Presenter: Kelly Rock, DNP, PMHNP-BC
Date Originally Presented: Wednesday, August 17, 2022
Time On Demand: Will be available until August 17, 2024
Summary:
After nearly 60 years on the U.S. market, benzodiazepine risks were 'officially' recognized by the FDA, necessitating changes in Boxed Warning language. This information was not widely disseminated to healthcare providers, pharmacists, or patients. Additionally, there is no widely accepted benzodiazepine guideline(s) in the U.S. that is used unequivocally across patient care settings that define rational use and protocols for de-prescribing. This presentation will identify commonalities across multiple rational-use and best practice guidelines, identify the necessity of informed consent, and review a number of evidence-based de-prescribing strategies.
Contact Hours:
This activity has been approved by the Ohio Nurses Association to award one contact hour. The Ohio Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91).
Criteria for Successful Completion
To obtain contact hour(s), one must attend the entire webinar and complete a post-webinar evaluation.
Conflict of Interest
No one with the ability to control content of this activity has a relevant financial relationship with an ineligible company.
Cost:
To Register: https://www.ispn-psych.org/benzodiazepine_utilization_webinar
Distributors may purchase multiple copies of packages to distribute to learners, and follow their progress. Bulk discounts are below.
| Quantity | Price per voucher |
|---|---|
| 1+ | $0.00 |